Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, Mai E, Young J, Johnson C, Huseni M, Wang X, Chen Y, Wang P, Wang H, Dybdal N, Chu YW, Chiorazzi N, Scheer JM, Junttila T, Totpal K, Dennis MS, Ebens AJ. Sun LL, et al. Among authors: clark r. Sci Transl Med. 2015 May 13;7(287):287ra70. doi: 10.1126/scitranslmed.aaa4802. Sci Transl Med. 2015. PMID: 25972002
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. Schaefer G, et al. Among authors: clark r. Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003. Cancer Cell. 2011. PMID: 22014573 Free article.
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, Young J, Luis E, Lewis Phillips G, Stefanich E, Spiess C, Polson A, Irving B, Scheer JM, Junttila MR, Dennis MS, Kelley R, Totpal K, Ebens A. Junttila TT, et al. Among authors: clark r. Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16. Cancer Res. 2014. PMID: 25228655
Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
Mandikian D, Takahashi N, Lo AA, Li J, Eastham-Anderson J, Slaga D, Ho J, Hristopoulos M, Clark R, Totpal K, Lin K, Joseph SB, Dennis MS, Prabhu S, Junttila TT, Boswell CA. Mandikian D, et al. Among authors: clark r. Mol Cancer Ther. 2018 Apr;17(4):776-785. doi: 10.1158/1535-7163.MCT-17-0657. Epub 2018 Jan 16. Mol Cancer Ther. 2018. PMID: 29339550
Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
Staflin K, Zuch de Zafra CL, Schutt LK, Clark V, Zhong F, Hristopoulos M, Clark R, Li J, Mathieu M, Chen X, Johnston J, Low J, Ybarra R, Slaga D, Yang J, Ovacik M, Dybdal NO, Totpal K, Junttila MR, Ellerman D, Lee G, Dennis MS, Prell R, Junttila TT. Staflin K, et al. Among authors: clark r, clark v. JCI Insight. 2020 Apr 9;5(7):e133757. doi: 10.1172/jci.insight.133757. JCI Insight. 2020. PMID: 32271166 Free PMC article.
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer.
Lo AA, Johnston J, Li J, Mandikian D, Hristopoulos M, Clark R, Nickles D, Liang WC, Hötzel K, Dunlap D, Pham T, Cai H, Ovacik M, Bravo-Perez D, Mai E, Slaga D, Ellerman D, Ziai J, Totpal K, Lee G, Boswell CA, Payandeh J, Wu Y, Junttila TT. Lo AA, et al. Among authors: clark r. Mol Cancer Ther. 2021 Apr;20(4):716-725. doi: 10.1158/1535-7163.MCT-20-0490. Epub 2021 Feb 3. Mol Cancer Ther. 2021. PMID: 33536191
Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P, Sun LL, Clark R, Hristopoulos M, Chiu CPC, Dillon M, Lin W, Lo AA, Chalsani S, Das Thakur M, Zimmerman Savill KM, Rougé L, Lupardus P, Piskol R, Husain B, Ellerman D, Shivva V, Leong SR, Ovacik M, Totpal K, Wu Y, Spiess C, Lee G, Leipold DD, Polson AG. Wang P, et al. Among authors: clark r. Mol Cancer Ther. 2022 Jun 1;21(6):974-985. doi: 10.1158/1535-7163.MCT-21-0599. Mol Cancer Ther. 2022. PMID: 35364611 Free PMC article.
7,393 results